AETHLON MEDICAL INC - AEMD STOCK NEWS

Aethlon Medical, Inc. (Nasdaq: AEMD) announced the appointment of Angela Rossetti to its Board of Directors, effective April 1, 2022. She replaces Sabrina Martucci Johnson, who steps down to focus on other roles. Rossetti brings over 20 years of biopharmaceutical experience, having held significant positions at various companies, including Pfizer. Her expertise in medical and clinical affairs is expected to boost the company's clinical advancements, particularly for the Hemopurifier, a device aimed at treating infectious diseases and cancer.

Aethlon Medical, Inc. (Nasdaq: AEMD) reported its financial results for the third quarter ending December 31, 2021. The company had a cash balance of approximately $20.4 million but recorded only $17,000 in revenue, a significant drop from $625,000 in the same period last year. Operating expenses decreased to $2.55 million, resulting in a net loss of about $2.5 million. Aethlon is advancing the Hemopurifier™ in clinical trials for Severe COVID and cancer, with progress made in patient enrollment across multiple sites.

Aethlon Medical, Inc. (Nasdaq: AEMD) will announce its financial results for Q3 FY2022, concluding on December 31, 2021, on February 14, 2022, at 4:15 p.m. EST. Management will hold a conference call at 4:30 p.m. EST to discuss these results and recent developments, followed by a Q&A session. The Hemopurifier, Aethlon's lead technology, is a FDA-designated Breakthrough Device aimed at treating advanced cancer and life-threatening infectious diseases. It has shown promising results in human studies, particularly in removing harmful viruses and exosomes from blood.

Aethlon Medical, Inc. (Nasdaq: AEMD) reported its financial results for the second quarter ended September 30, 2021, highlighting ongoing developments for the Hemopurifier™, a blood filtration system targeting COVID-19 and cancer. As of September 30, the company had $23.2 million in cash and generated $132,000 in government contract revenue, compared to none in the same quarter last year. Operating expenses rose to $2.1 million, resulting in a net loss of approximately $2.0 million. The company is advancing U.S. clinical trials and has expanded its international presence with a trial in India.

Aethlon Medical (AEMD) will announce its second quarter fiscal year 2022 financial results on November 9, 2021, at 4:15 p.m. EST. A conference call will follow at 4:30 p.m. EST, where management will discuss the financial results and corporate developments. The Hemopurifier, Aethlon's lead technology, targets life-threatening infections and cancer, and has received FDA Breakthrough Device designation. The company is conducting an Early Feasibility Study at the University of Pittsburgh to evaluate the Hemopurifier's effects on cancer-associated exosomes.

Aethlon Medical, Inc. (AEMD) has published a manuscript in Frontiers in Medicine detailing two case studies of critically ill COVID-19 patients treated with the Hemopurifier® blood filtration system. The study shows the Hemopurifier®'s ability to remove SARS-CoV-2 virus, exosomes, and exosomal microRNAs, with one patient experiencing clinical improvement. The device is undergoing an Early Feasibility Study to evaluate its safety in treating up to 40 COVID-19 ICU patients. Aethlon holds FDA Breakthrough Device designations for its applications in cancer and life-threatening viral diseases.

Aethlon Medical, Inc. (Nasdaq: AEMD) has announced a partnership with PPD, Inc. (Nasdaq: PPD) to manage clinical studies for its Hemopurifier, a therapeutic blood filtration system focused on treating infectious diseases, including COVID-19. Under this agreement, PPD will oversee ongoing clinical trials and may expand to additional studies. The Hemopurifier has received FDA Breakthrough Device designation and has shown promise in removing harmful viruses and exosomes in prior studies. This collaboration aims to expedite the clinical development for critically ill patients.

Aethlon Medical, Inc. (Nasdaq: AEMD) will present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference from September 13-15, 2021. CEO Charles J. Fisher will offer an overview on September 13 at 7:00 AM EDT, available on-demand for 90 days. Aethlon’s Hemopurifier, a clinical-stage device for treating cancer and viral infections, holds FDA's Breakthrough Device designation. The company also operates Exosome Sciences, focused on exosomal biomarkers for cancer and neurological diseases.

Aethlon Medical, Inc. (Nasdaq: AEMD) reported financial results for Q1 ended June 30, 2021, highlighting continued clinical development of the Hemopurifier for COVID-19. The company raised $17.5 million from common stock sales, bringing cash reserves to $25.2 million. Total government contract revenue was approximately $132,000. Operating expenses increased to $2.2 million, leading to a net loss of $2.1 million, up from $1.4 million year-over-year. The company is negotiating with additional clinical centers for trials, with a focus on potential treatments for SARS-CoV-2.